<DOC>
	<DOCNO>NCT00037687</DOCNO>
	<brief_summary>The objective study demonstrate rPAF-AH safe reduces 28 day cause mortality patient severe sepsis .</brief_summary>
	<brief_title>Safety Efficacy Recombinant Human Platelet-Activating Factor Acetylhydrolase Treatment Severe Sepsis</brief_title>
	<detailed_description>This study randomize , double-blind , placebo-controlled , multicenter study rPAF-AH compare placebo patient severe sepsis . Eligible patient investigative site locate throughout United States country randomize receive either rPAF-AH placebo administer daily five consecutive day intravenous ( IV ) infusion . All patient evaluate safety efficacy endpoints 28 day . A follow-up evaluation occur approximately 6 month Day 28 ass functional status quality life .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<criteria>Inclusion criterion Clinical diagnosis severe sepsis At least 18 year old Patient legally authorize representative able provide inform consent Exclusion criterion Severe lung injury ( acute respiratory distress syndrome ) Immunocompromised Severe liver disease Inflammation pancreas , organ rejection , burn 30 % body Enrolled another clinical trial Already participate rPAFAH study There commitment aggressive treatment Has disease life expectancy le 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2003</verification_date>
	<keyword>Severe sepsis</keyword>
	<keyword>Platelet-activating factor acetylhydrolase</keyword>
</DOC>